Dr. Solanki shares that in conversations with the public, he regularly encounters misinformation, like "Is pharma holding back the cure for cancer?". This highlights a critical and persistent reputation challenge for the industry that scientific leaders must be prepared to address directly and patiently, rather than ignoring.
Dr. Solanki's path into oncology wasn't planned. His initial interest was sparked by safety warnings on lab chemicals, not a desire to treat disease. This "accidental" interest, combined with early networking, led to a specialized postdoc and a 15+ year career, showing that passion can be discovered, not just declared.
Dr. Saav Solanki observes that many breakthrough medicines don't follow a linear path within one organization. Instead, they are developed collaboratively, often starting in a university lab, moving to a small biotech for initial development, and finally being acquired or licensed by a large pharma company for commercialization.
While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.
Only 5% of investigational cancer drugs reach the market due to the gap between lab models and human biology. Dr. Saav Solanki highlights organoids, which use real patient tissue, as a key translational model to improve the predictive accuracy of preclinical research and increase the low success rate.
Dr. Saav Solanki argues that effective communication is more than half the battle in science. He believes the best scientists are those who can explain complex topics, like how a T-cell engager works, with enough clarity for a high school student to understand, which is essential for fostering collaboration and broader support.
Dr. Solanki's career advice goes beyond typical networking. He recommends studying the career trajectories of others to identify pivot points and, crucially, integrating AI tools like ChatGPT on a daily basis. He warns that failing to stay on top of technology will leave scientists behind, regardless of their field.